MiRagen Therapeutics Garners $41,000,000 Series C Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=801da261-b429-4043-849e-d66b14fca2f9
Date
11/10/2015
Company Name
MiRagen Therapeutics
Mailing Address
6200 Lookout Rd. Boulder, CO 80301 USA
Company Description
Miragen was founded in 2007 to exploit recent discoveries showing that specific perturbations in microRNA expression are correlated with various forms of cardiovascular disease.
Website
http://www.miragentherapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$41,000,000
Transaction Round
Series C
Proceeds Purposes
miRagen plans to use the proceeds from the financing to advance two product candidates, MRG-106 and MRG-201, into clinical development this year. Gross proceeds of $41 million included conversion of outstanding notes.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor